Rocket Pharmaceuticals, Inc.

Jonathan joined Rocket as founding Chief Medical Officer in 2016 and has been instrumental in crafting and advancing an industry-leading pipeline of gene therapy programs across AAV cardiology and LV hematology portfolios.

Mr. Boess has served as a director of Inotek / Rocket Pharmaceuticals since January 2016.

Inotek merged with Rocket in January 2018.

Martin joined the company in December 2021 as its founding General Counsel & Chief Compliance Officer.

J&J becoming the top hematology company worldwide in 2024.

Prior to joining Rocket in April 2025, Sarbani was Vice President at Johnson & Johnson Innovative Medicine leading hematology.

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy poster

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket’s First FDA Gene Therapy Approval

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher